CD27 is a new promising T-cell co-stimulatory target for cancer immunotherapy
Thierry Guillaudeux, Phd, Chief Scientific Officer Society for Immunotherapy of Cancer (SITC) 2023 | November 3, 2023
CD27 an emerging immuno-oncology target at the cross-roads of innate and adaptive anti-tumor immune responses
Thierry Guillaudeux, Phd, Chief Scientific Officer American Association for Cancer Research (AACR) Conference on Tumor Immunology and Immunotherapy 2022 | December, 2022
CD27 a new immuno-oncology target shaping innate and adaptive anti-tumor immune responses
Thierry Guillaudeux, Phd, Chief Scientific Officer American Association for Cancer Research (AACR) Annual Meeting 2022 | April 13, 2022
Novel fully human agonist antibodies against the T-cell costimulatory receptor CD27 shape adaptive anti-tumor immunity
Thierry Guillaudeux, Phd, Chief Scientific Officer European Society for Medical Oncology (ESMO) Immuno-Oncology Congress | December 8-11, 2021
A promising cancer immunotherapy target: Novel agonistic human antibodies against the human T-cell costimulatory receptor CD27
Thierry Guillaudeux, Phd, Chief Scientific Officer Society for Immunotherapy of Cancer (SITC) 36th Anniversary Annual Meeting | November 13, 2021
A promising cancer immunotherapy target: Novel agonistic human antibody against the human T-cell costimulatory receptor CD27
Thierry Guillaudeux, Phd, Chief Scientific Officer American Association for Cancer Research (AACR) Virtual Special Conference on Tumor Immunology and Immunotherapy | October 5-6, 2021